Please provide your email address to receive an email when new articles are posted on . Empagliflozin is beneficial in patients with HF and all stages of chronic kidney disease. The SGLT2 inhibitor ...
The US Food and Drug Administration has approved sotagliflozin for the prevention of cardiovascular death, hospitalization for heart failure (HF), and urgent heart failure visits in adults with heart ...
BARCELONA, Spain—(UPDATED) Full results of the DELIVER trial, flanked by several other analyses, demonstrate that the sodium-glucose cotransporter 2 (SGLT2) inhibitors provide benefits to patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback